Product Description
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Italy
Approved Indications: None
Known Adverse Events: None
Company: Beersheva Mental Health Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Psychotic Disorders|Schizophrenia|Affective Disorders, Psychotic|Bipolar Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BMHC-3658 | P3 |
Completed |
Psychotic Disorders|Schizophrenia|Affective Disorders, Psychotic|Bipolar Disorder |
None |